Receptors, Vasopressin

• 

  Subject Areas on Research

  • A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. 
  • Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. 
  • Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • BiPS, a photocleavable, isotopically coded, fluorescent cross-linker for structural proteomics. 
  • Cardiac function and heart failure. 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. 
  • Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. 
  • Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. 
  • Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. 
  • Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. 
  • Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. 
  • Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. 
  • G Protein and β-arrestin signaling bias at the ghrelin receptor. 
  • G protein G(alpha)o is essential for vomeronasal function and aggressive behavior in mice. 
  • Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). 
  • Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007. 
  • Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients. 
  • Hyponatremia treatment guidelines 2007: expert panel recommendations. 
  • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. 
  • Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction. 
  • Phosphorylation analysis of G protein-coupled receptor by mass spectrometry: identification of a phosphorylation site in V2 vasopressin receptor. 
  • Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). 
  • Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. 
  • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. 
  • Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. 
  • Respiration during acute hypoxia: angiotensin- and vasopressin-receptor blocks. 
  • Role of vaptans in the management of hyponatremia. 
  • Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. 
  • Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. 
  • Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. 
  • The potential repertoire of the innate immune system in the bladder: expression of pattern recognition receptors in the rat bladder and a rat urothelial cell line (MYP3 cells). 
  • Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure? 
  • Treatment of chronic hyponatremia: now we know how, but do we know when or if? 
  • Vasopressin receptor antagonists. 
  • Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. 
  • Vasopressin: a new target for the treatment of heart failure. 
  • Ventilatory and metabolic effects of hypercapnia in conscious rats: AVP V1 receptor block. 
  • Weak effects of common genetic variation in oxytocin and vasopressin receptor genes on rhesus macaque social behavior. 
  • When is it appropriate to use vasopressin receptor antagonists? 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology